CRVW — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-13

• On July 1, 2025, we extended our HealthTrust Purchasing Agreement through June 30, 2028.

• Accounting standards require management to evaluate whether the Company can continue as a going concern for a period of one year after the date of the filing of this Form 10-Q (“evaluation period”). In evaluating the Company’s ability to continue as a going concern, management considers the conditio…

• In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update will improve the transparency and usefulness of income tax disclosures. Investors, lenders, and creditors have indicated that current disclosures do not provide enough detaile…

• In November 2024, the FASB issued ASU No. 2024-04, “Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments,” which clarifies the criteria for determining when a settlement of convertible debt should be accounted for as an induced conversion. The…

• In July 2025, the FASB issued ASU 2025-05, "Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets," which amends how entities estimate expected credit losses for current accounts receivable and current contract assets arising from r…

Text removed vs the prior filing · source: 10-Q · 2025-11-13

• Nine months ended September 30, 2025, compared to nine months ended September 30, 2024

• Revenue increased approximately $574,000 for the nine months ended September 30, 2025, as compared to the same period in 2024. The increase was driven by revenues from recurring annual software recognized over time.

• Our principal operating costs include the following items as a percentage of total operating expenses.

• Human resource costs, including benefits and non-cash compensation

• Other product deployment costs, excluding human resources and travel and entertainment costs

Text added vs the prior filing · source: 10-Q · 2026-05-13

• With the participation of our Principal Executive Officer and Principal Financial Officer, management has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, management concluded that, due to a material w…

• Management's Reporting on Internal Control Over Financial Reporting

• Management is responsible for establishing and maintaining adequate internal control over financial reporting (“ICFR”) as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our ICFR is designed to provide reasonable assurance regardin…

• Management, under the supervision and with the participation of our Chief Executive Officer, Steve G. Johnson, and our principal financial and chief accounting officer, Jason T. Thompson, evaluated the effectiveness of the Company’s ICFR as of March 31, 2026. In making this assessment, management us…

• Based on this evaluation, management concluded that the Company’s ICFR was not effective as of March 31, 2026 due to the existence of a material weakness in internal control over financial reporting described below.

Text removed vs the prior filing · source: 10-Q · 2025-11-13

• Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), we carried out an evaluation, with the participation of our management, including Steve G. Johnson, our Chief Executive Officer (“CEO”) and principal executive officer, and Jason T. Thompson, our principal financi…

• Under the supervision and with the participation of our CEO and principal financial and chief accounting officer, our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2025. Based on that evaluation, our CEO and principal…

• A material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. …